BioVersys SAS

Quick facts

Phase 3 pipeline

• BV100 (300 mg) · Infectious Disease
  BV100 is a benzoxaborole antibiotic that inhibits bacterial leucyl-tRNA synthetase, disrupting protein synthesis in susceptible pathogens.
• MEROPENEM 2 grams TID · Infectious Disease
  Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BioVersys SAS portfolio CI brief
• BioVersys SAS pipeline updates RSS